NCT06545942 - Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors | Biotech Hunter

Enrollment

158

Participants

Timeline

Start Date

August 13, 2024

Primary Completion Date

May 31, 2027

Study Completion Date

November 30, 2027

Conditions

Advanced Solid TumorMetastatic Solid TumorProstate CancerPancreas CancerBreast CancerOvarian CancerHomologous Recombination Deficiency

Interventions

DRUG

MOMA-313

MOMA-313 administered orally

DRUG

Olaparib

Olaparib administered orally

Trial Locations (18)

10016

RECRUITING

Investigative Site #103, New York

10065

RECRUITING

Investigative Site #106, New York

19104

RECRUITING

Investigative Site #109, Philadelphia

22031

RECRUITING

Investigative Site #112, Fairfax

29572

RECRUITING

Investigative Site #107, Myrtle Beach

32746

RECRUITING

Investigative Site #104, Lake Mary

37203

RECRUITING

Investigative Site #102, Nashville

63110

RECRUITING

Investigative Site #110, St Louis

78229

RECRUITING

Investigative Site #105, San Antonio

85338

RECRUITING

Investigative Site #108, Goodyear

92093

RECRUITING

Investigative Site #101, La Jolla

94143

RECRUITING

Investigative Site #111, San Francisco

Unknown

RECRUITING

Investigative Site #114, Barcelona

RECRUITING

Investigative Site #116, Barcelona

RECRUITING

Investigative Site #115, Madrid

RECRUITING

Investigative Site #113, London

RECRUITING

Investigative Site #117, Manchester

RECRUITING

Investigative Site #118, Newcastle upon Tyne